Evolent Health, Inc. logo

Evolent Health, Inc.

EVH

NYSEHealthcareMedical - Healthcare Information Services

Previous close

$4.74

+$0.04 · +0.85%

Aug 21, 4:00 PM ET

EVH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

36

Expensive

Momentum

64

Gaining

Sentiment

63

Bullish

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
Headquarters
US
CEO
Seth Barrie Blackley
Listed since
Jun 5, 2015
Employees
4,200

Market position

Day range

Current $4.74

52-week range

Current $4.74

Open
$4.61
Previous close
$4.70
Volume
1.68M
0.56× average
Average volume
2.99M
Average daily volume
Market cap
533.16M USD
Beta
0.78
Market reference 1
50-day average
$4.7594
-0.41% below average
200-day average
$3.8815
+22.12% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.29B USD
P/E (TTM)
-1.06×
P/B (TTM)
1.39×
P/S (TTM)
0.25×
EV / EBITDA
-3.58×
Earnings yield
-117.00%
Free cash flow yield
1.04%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
12.92%
Operating margin
-1.37%
Net margin
-24.08%
Return on equity
-128.74%
Return on assets
-28.14%
Return on invested capital
-0.29%

Financial health

Debt / equity
2.53×
Current ratio
1.31×
Altman Z-score
-0.36
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends33%11%-12%-34%Gross margin, FY2021: 27.58%Gross margin, FY2022: 23.42%Gross margin, FY2023: 23.45%Gross margin, FY2024: 14.38%Gross margin, FY2025: 15.14%Operating margin, FY2021: -4.67%Operating margin, FY2022: 0.27%Operating margin, FY2023: -3.63%Operating margin, FY2024: -1.58%Operating margin, FY2025: -0.24%Net margin, FY2021: -4.14%Net margin, FY2022: -1.42%Net margin, FY2023: -5.76%Net margin, FY2024: -2.41%Net margin, FY2025: -28.49%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 27.58%. Gross margin FY2022 23.42%. Gross margin FY2023 23.45%. Gross margin FY2024 14.38%. Gross margin FY2025 15.14%. Operating margin FY2021 -4.67%. Operating margin FY2022 0.27%. Operating margin FY2023 -3.63%. Operating margin FY2024 -1.58%. Operating margin FY2025 -0.24%. Net margin FY2021 -4.14%. Net margin FY2022 -1.42%. Net margin FY2023 -5.76%. Net margin FY2024 -2.41%. Net margin FY2025 -28.49%.

Income trends

Revenue

1.88B USD-26.56%

Operating income

−4.44M USD+89.05%

Net income

−534.51M USD-767.39%
Income trends across reported periods2.86B USD1.63B USD392.27M USD−843.44M USDRevenue, FY2021: 907.96M USDRevenue, FY2022: 1.35B USDRevenue, FY2023: 1.96B USDRevenue, FY2024: 2.55B USDRevenue, FY2025: 1.88B USDOperating income, FY2021: −42.41M USDOperating income, FY2022: 3.64M USDOperating income, FY2023: −71.21M USDOperating income, FY2024: −40.49M USDOperating income, FY2025: −4.44M USDNet income, FY2021: −37.6M USDNet income, FY2022: −19.16M USDNet income, FY2023: −113.04M USDNet income, FY2024: −61.62M USDNet income, FY2025: −534.51M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 907.96M USD. Revenue FY2022 1.35B USD. Revenue FY2023 1.96B USD. Revenue FY2024 2.55B USD. Revenue FY2025 1.88B USD. Operating income FY2021 −42.41M USD. Operating income FY2022 3.64M USD. Operating income FY2023 −71.21M USD. Operating income FY2024 −40.49M USD. Operating income FY2025 −4.44M USD. Net income FY2021 −37.6M USD. Net income FY2022 −19.16M USD. Net income FY2023 −113.04M USD. Net income FY2024 −61.62M USD. Net income FY2025 −534.51M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.88B USD2.55B USD1.96B USD1.35B USD907.96M USD
Cost of goods sold1.59B USD2.19B USD1.5B USD1.04B USD657.55M USD
Gross profit284.03M USD367.35M USD460.47M USD316.58M USD250.41M USD
Research and development27M USD
Selling, general, and administrative288.47M USD263.05M USD358.11M USD269.27M USD219.5M USD
Operating expenses288.47M USD407.84M USD531.68M USD312.94M USD292.82M USD
Interest income4.19M USD5.54M USD5.26M USD1.37M USD407K USD
Interest expense57.47M USD24.72M USD54.21M USD15.57M USD25.43M USD
Depreciation and amortization115.85M USD123.17M USD123.42M USD90.25M USD60.04M USD
Operating income−4.44M USD−40.49M USD−71.21M USD3.64M USD−42.41M USD
Net income−534.51M USD−61.62M USD−113.04M USD−19.16M USD−37.6M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+10.27%
11 comparable reports
Latest EPS result
0.02
Estimate -0.01 · Beat by 292.12%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.420.230.05-0.14Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual -0.02, estimate 0.38, surprise -105.26%, Miss. Q2 2025, reported May 8, 2025: actual 0.06, estimate 0.09, surprise -33.33%, Miss. Q3 2025, reported Aug 7, 2025: actual -0.1, estimate 0.09, surprise -211.11%, Miss. Q4 2025, reported Nov 6, 2025: actual 0.05, estimate 0.1, surprise -50.00%, Miss. Q1 2026, reported Feb 24, 2026: actual 0.08, estimate 0.06, surprise +33.33%, Beat. Q2 2026, reported May 7, 2026: actual -0.02, estimate -0.05, surprise +60.00%, Beat. Q3 2026, reported Aug 6, 2026: actual 0.02, estimate -0.01, surprise +292.12%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 0.08, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates757.71M643.54M529.36M415.19MQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 20, 2025: actual 646.54M USD, estimate 650.92M USD, surprise -0.67%, Miss. Q2 2025, reported May 8, 2025: actual 483.65M USD, estimate 460.28M USD, surprise +5.08%, Beat. Q3 2025, reported Aug 7, 2025: actual 444.33M USD, estimate 532.2M USD, surprise -16.51%, Miss. Q4 2025, reported Nov 6, 2025: actual 479.53M USD, estimate 468.48M USD, surprise +2.36%, Beat. Q1 2026, reported Feb 24, 2026: actual 468.72M USD, estimate 468.66M USD, surprise +0.01%, Beat. Q2 2026, reported May 7, 2026: actual 496.25M USD, estimate 534M USD, surprise -7.07%, Miss. Q3 2026, reported Aug 6, 2026: actual 652.52M USD, estimate 597.69M USD, surprise +9.17%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 728.57M USD, surprise —, Comparison unavailable.

EVH news

EVH peers

ETFs holding EVH

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research EVH

research.disclaimer